Stephen Gracon, D.V.M., Joins the NanoBio Team as Vice President of Regulatory Affairs

Stephen Gracon, D.V.M., Joins the NanoBio Team as Vice President of Regulatory
Affairs

ANN ARBOR, Mich., Jan. 15 /PRNewswire/ -- NanoBio(R) Corporation, a
biopharmaceutical company focused on developing and commercializing novel
products for the prevention and treatment of infectious diseases, today
announced the addition of Stephen Gracon, D.V.M., as Vice President of
Regulatory Affairs.
In his new role, Dr. Gracon will lead the regulatory and quality assurance
activities for the company's rich pipeline of anti-infective products and
mucosal vaccines.
Dr. Gracon brings 30 years of experience to NanoBio in diverse areas
within the pharmaceutical industry, including pathology and experimental
toxicology, clinical research, and regulatory affairs within the United States
and internationally. Dr. Gracon served in various clinical, research and
regulatory positions at Parke-Davis, Pfizer, Amgen and Baxter prior to joining
NanoBio. He has a unique combination of experience with both small and large
molecules in a broad range of indications, as well as with seasonal and
pandemic vaccines and plasma-derived products.
"NanoBio's platform is very unique and has tremendous potential far beyond
the current indications under investigation," said Dr. Gracon. "My role is to
develop and execute strategies with the NanoBio team to navigate and expedite
the FDA approval process for the numerous topical agents and vaccines that can
be developed from our proprietary nanotechnology platform."
"We are very fortunate to have Dr. Gracon's extensive regulatory
experience as we prepare for multiple regulatory submissions," added James
Baker Jr., M.D., founder and CSO of NanoBio Corporation. "His specialized
knowledge of regulatory protocol for both therapeutics and vaccines will be
critical to moving NanoBio's products to FDA approval."
About NanoBio
NanoBio(R) Corporation is a privately held biopharmaceutical company
focused on developing and commercializing anti-infective products and mucosal
vaccines derived from its patented NanoStat(TM) technology platform. The
company's lead product candidates are treatments for herpes labialis (cold
sores), onychomycosis (nail fungus), MRSA and mucosal vaccines for influenza
and hepatitis B. The company's headquarters and laboratory facilities are
located in Ann Arbor, Mich.
SOURCE NanoBio Corporation

John Coffey, Vice President of Business Development of NanoBio Corporation,
+1-734-302-9107, john.coffey@nanobio.com